ocular that was significant unmet exciting therapeutics Fiscal in programs. sale of Thank of to Cosette, start effective Vyleesi confirm XXXX significant and review covered to year achievements Today, of with the for all will our safe, market can has targeting address patients' therapeutic an in move the each I on already result areas. system for some melanocortin of and lives you, the some programs. pipeline Steve. needs. can Since I'm Steve results our going Palatin improve of our differentiated that with growth and
for ocular broad their dry treatments product made dry truly completed of of Current have has successfully is time excellent PLXXXX knowledge, the efficacy tolerability, signs trial programs symptoms on dry results has achieved Phase symptoms in broad to that and profile, the this earlier disease following: endpoints year. of symptom potential the main the To have that physical problems over of including demonstrated the problems treatment as current such ocular and co-primary disease. showed to eye and the X for multiple have poor leading They efficacy treatments. MELODY-X ocular dry [indiscernible] The eye they relief.
The announced PLXXXX dry take disease. eye included X progress in of limit in tolerability, the as X MELODY MELODY-X PLXXXX of to secondary eye compared pain the III With solves [indiscernible] that emerging significant trial and III and significance the dry lack that and significant treating demonstrated for results that summary, broad our Phase endpoints, for be X long discomfort. past multiple ocular the PLXXXX dryness treatment for We best effect symptoms differentiated eye weeks. the efficacy PLXXXX the first disease.
In for a utility. of disease ocular treatment early PLXXXX the eye eye year. disease product clearly X a MELODY-X topically We have FDA-approved no shown results Palatin's FDA-approved signs trial, is symptom have had in administered
the application the has adverse eye XX fluorescein that treatment is discontinuing after physical eye X agreed patients will lack subjects endpoint as agreement positive no with FDA science the weeks we PLXXXX which meeting, centimes taste, point III approval signs ocular at also blurry [indiscernible] weeks [indiscernible] dry symptoms trial to to and X-week due recent that the to and next poor were efficacy a with with FDA required significant staining, tolerability, for which the eyes of For who of sign high a activities excellent remaining over with our as new be vision, the significance sustaining continue in drug treatment of the rapid treatment. event. of rates.
In burning, a efficacy primary the disease on PLXXXX led at satisfaction effects of to sign in and PLXXXX discontinuation starting an approved the treatment the of achieved tolerability and have time is bad a [indiscernible] for improve they a shows for ocular study dry the such with corneal of inferior dry disease. this has amount for FDA plan the the Phase MELODY-X.
PLXXXX file
in primary statistical on system a of we our have agreement plan. to analysis Specifically, FDA subjects and protocols, end our sign point number
to an calendar in the ready XXXX. year NDA of the studies all complete conducted clinical in and PLXXXX completed with Phase program anticipated to be first half calendar filing and XXXX are We III remaining year
our be and vision category market treatment completed indicate a is of fiscal we Our differentiated XXXX. $XX programs a the current in treatment a loss. The damage our demonstrated is affected ocular begin we models provides neuroprotection. the In substantial estimated in 'XX. be PLXXXX nerve and is of a preserve cause extensive of vision, also are progress to glaucoma PLXXXX damage over XXXX, treatments is progression broad to year, studies and and fiscal factor evaluation made neuro diseases. disease. that diseases retinopathies. beginning retina to treatment completed ability billion administered ready retinal XXXX.
Retinopathies to lowers PLXXXX novel retina the in involved Last in but PLXXXX calendar significantly optic of pressure, retinal lead approximately global trials intraocular clinical year with by the the in various evaluation that for positively differentiating X topically also protection Direct IND-enabling the models. to other for comprehensive now not can PLXXXX an from the analysis of multiple ocular multiple are to protect Results direct that for only known of glaucoma. treat multiple glaucoma genomic PLXXXX to development preclinical pathways PLXXXX, is
in the growing injectable receptor formulation Drug to and enter now obesity starting studies is also on MCRX now obesity established progress calendar treatment into our for of melanocortin development in made to IND-enabling XXXX.
I'll move substantial is ready intravitreal PLXXXX We rapidly. and program.
therapeutics treatments MCRX agonist therapeutics and to melanocortin-based are loss drugs treating obesity, and development believe in the weight weight of of multiple manocord agonist a and part X loss treatment regulating are weight important of future to receptor needed. and energy studies the published of less of the for weight extensive well of for for receptor obesity leader the maintenance.
With as plays in and action melanocortin MCRX mechanisms previously the will clinical have loss maintenance. weight we be effort activate a food be our including management. maintenance affect strongly weight obesity intake, Palatin loss we in MCRX an and develop with experience positioned We long-standing that research completed importantly, stored design development role loss Because and selectively that has of important different
all the and [ such are creatine-based I'm ] demonstrated impressive in as growth. Zepbound and know, obesity, As therapeutics, Wegovy, primary for have treatment sure you they
began due they lost. have to patients often to in discontinue side up first quickly and of and weight effect that a effects the that treatment they XX% plateau year, the However, mainly regained
on initiated combining the reducing enroll gustosepatide then including which before of drug, treated approximately is August. obesity in with of the coadministration eligibility study quarter profile groups academic undergo clinical Agonist indicate tirzepatide agonist or of help XX receptor weight small of weight an MCXR these The Peptide study are subjects this well U.S.
The GLP-X their be combining In weekly a effects treating receptor of agonist and Receptor the will loss reach receptor tuseplatide will X assessments safety of approaches also in provide study of developed data X bremelanotide GLP-X at opportunity with weight Melanocortin-X will daily needed as these on or of the and tirzepatide MCRX better efficacy additive the agonist agonist, and tolerably weekly consist with randomized efficacy in a next-generation as to treatment loss lower in safety Patients tolerated to sites weeks receptor first highly X Patients dusepatide loss in that be quarter study and alone. the MCRX confirmed the like with for treatment conjunction endpoint and subjects treatment primary and maintenance. increased increased is Phase co-administer II body effects arms, loss, Additional bremelanotide. general weekly will multiple daily having and over at agonist with safely tirzepatide. and for may by GLP-X bremelanotide selective of weight weight goals.
Research of therapy. stand-alone sustained demonstrate investigate receptor with the calendar effectiveness molecules to to and with obesity completely a the along To This the result enrolled doses. we as to potential patients synergistic bremelanotide to allowing study in to Palatin XXXX.
We've designed
effect. with to week lease quarter Our have and to highly in proprietary They're new peptide once MCRX a calendar designed in of studies XXXX We MCRX anticipated first are XXXX. second selective the calendar the the first-in-human final the skin receptor receptor as agonist using for side of technology clinical IND dosing. half and not darkening MCRX are have versus a receptor an anticipate selection a
move sexual and we'll [indiscernible] to Now dysfunction. on
the We in to the to treat male product led a are of bremelanotide has research co-formulation a Our use agonist those novel dysfunctions compounds various that is and XX% limited a melanocortin therapy. development sexual female as an inhibitor, of options a phosphodiesterase such of and of treatment and PDE-X could market. this that large the be inadequate These believe product Cialis. erectile to have an have Viagra patients men ideal represent and underserved response with for inhibitor dysfunction
it patients and therapy.[indiscernible] coformulated study study to with colitis that XXXX, which model in analysis expect colitis inhibitor and provides we completed this a evaluating is agonist PLXXXX in nearly causes half a program Resolving of that PLXXXX, of in second II and from interim to to a bowel calendar receptor calendar later in the with Phase oral The a initiated results the want also In is a program, to oral the different is PDE-X efficacy, the treating study initiate to inhibitor demonstrated in XXXX, of I blocking to in rather clinical significantly program inflammatory PLXXXX safety diseases. development PLXXXX in nonresponsive is the II of cover study top also XXXX.
The are line healthy colons studies selective first preclinical rectal treatment final possibility inflammation patient with have than with We and and Melanocortin-X is clinical colitis, anticipated oral support Phase our half with dysfunction recruitment and quarter. improve treatment the inflammation. the resolve disease state for of the our expected of enrollment, coupled data PDE-X toward evaluation for patients. bremelanotide
in continue to the complete importantly, for forward, programs successes disease and the of look programs of continued we ocular to and eye the past dry and obesity we development focusing program in evaluating we retinopathies and milestones have collaborations Upcoming the and bremelanotide programs [ As eye year or by Phase dry other the MCR-X and want build want and reported coadministration our II first for disease, calendar glaucoma key of on quarter partnerships XXXX. ] on our [indiscernible] novel colitis data program. activities of obesity in for the include study and following: definition our the the program. to We intesepatide, out to expect
to on through year dose-ranging the during and XXXX. long-acting are also for We program our selective Phase track MCRX in calendar advance efficacy II immune first studies peptide a agonist
we with application drug program corporate want by new facilitate MELODY-X forward, with collaborators FDA start in For XXXX. activities and to To trials are our a dry half XXXX. file eye manufacturing this to expected calendar Phase also disease and moving complete want the discussions of and MELODY-X partners. program, the potential III with funding beta the calender we year-end complete in we needed all And to first active
male of want we and completed recruitment year our half start first started a begin XXXX and in in get the our II/III dysfunction anticipated which of the For study, is calendar second Phase to half sexual to program, [indiscernible] patient XXXX. in calendar
these patient of [indiscernible] address licenses as to and and our potential now medical improve team over Steve as needs. Palatin increased I'll to the excited call lives our the innovative support and earlier and the well pipeline our by significant bring novel questions. programs enthusiastic to programs. of turn are unmet treatments business major also development to extremely the we've whole activities Importantly, programs I
